C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. As of December 31, 2010, the Company sold a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The company operates in four product group categories: vascular, urology, oncology and surgical specialties. The company also has a product group of other products. On July 6, 2010, the Company completed the acquisition of SenoRx, Inc. On May 20, 2010, the Company, through its wholly owned subsidiary, Bard Holdings Limited, acquired its Malaysian manufacturing operation. On April 12, 2010, the Company completed the acquisition of the outstanding stock of FlowCardia, Inc. (FlowCardia), engaged in the design and manufacture of endovascular products used in the treatment of chronic total occlusions (CTOs).